Lupin gets EIR for Somerset manufacturing facility

21 Feb 2025 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from January 27 to January 31, 2025. 

Earlier, the company had received ‘A-’ leadership rating from CDP for its outstanding performance in climate change and water security. This rating reflects Lupin's leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×